Investigation: Leen Kawas
Former Athira Pharma CEO Leen Kawas is the subject of HHS Office of Research Integrity findings of image falsification in her doctoral and published research, which were cited in NIH grant applications and triggered a $4.07 million False Claims Act settlement against Athira Pharma. Following her 2021 resignation, Kawas launched Propel Bio Partners LLC, a reported $150 million biotech investment fund, raising material questions about disclosure of her regulatory record to new investors.
Investigation Overview
Investigation Overview
Post-Misconduct Career Rehabilitation and Investor Disclosure Risk
DOJ filings, ORI findings, media reportsIncludes DOJ press release and Chemistry World
FCA settlement and qui tam action
Primary source documents
Federal and Washington State
This investigation examines the professional arc of Leen Kawas from her tenure as CEO of Athira Pharma through her post-departure founding of Propel Bio Partners LLC, against the backdrop of HHS Office of Research Integrity findings and a federal False Claims Act settlement. The investigation focuses on the contradiction between an established adverse regulatory record and a public-facing professional narrative that does not consistently incorporate that record.
The factual core is settled: ORI findings concluded that Kawas altered scientific images in her doctoral dissertation and at least four published research papers; Athira Pharma settled federal allegations for $4.07 million in January 2025 for failing to disclose those allegations to NIH across a five-year window from January 2016 to June 2021. A whistleblower received $200,000 under qui tam provisions.
Methodology relies on open-source intelligence drawn from DOJ filings, trade press (Chemistry World), investigative media (OCCRP), and self-presentation channels. All allegations remain unproven beyond the regulatory and settlement record specifically established. Active verification gaps are flagged throughout.
Subject Profile
Biographical and credential analysis
Biographical Data
Career Overview
Kawas completed her doctoral dissertation at Washington State University in 2011 and subsequently published research from 2011 through 2014, materials later identified by HHS ORI as containing falsified or manipulated scientific images. She co-founded Athira Pharma and rose to serve as Chief Executive Officer of the company, overseeing its public listing on NASDAQ and its development of ATH-1017 for Alzheimer's disease.
Kawas resigned from Athira Pharma in October 2021 following the conclusion of an investigation into her image manipulation during her graduate work. Following her departure, she founded Propel Bio Partners LLC, a private investment fund reported to target $150 million in capital, with an investor base described in trade media as including individuals with ties to Athira Pharma.
Credential Analysis
Corporate Structure Analysis
Entity mapping and ownership
Registered Entities
Washington State, 2011
Public biopharmaceutical company (NASDAQ: ATHA); subject of $4.07M FCA settlement
United States (post-2021)
Private biotech investment fund founded by Kawas; reported $150M target
Ownership Structure
Kawas's ownership of Propel Bio Partners LLC is implied by founder/managing principal status; specific membership interest percentages, co-founders (if any), and capital structure are not publicly verifiable from open-source inputs. Formation filings, registered agent details, and state of incorporation require active records retrieval.
The reported overlap between Propel Bio Partners' investor base and individuals with prior ties to Athira Pharma — described by trade media as 'key investors from former company' — represents a material continuity in capital network. Whether those investors had full disclosure of ORI findings and FCA settlement at point of LP commitment is the central unresolved governance question.
Legal Case Analysis
Federal settlement and qui tam resolution
Legal Case Tracker
2 cases · 2025–2025
Click any node on the timeline to view case details
United States v. Athira Pharma Inc.
US District Court, W.D. Washington — 2025
$4.07 million False Claims Act civil settlement announced January 2025 by the U.S. Attorney's Office for the Western District of Washington. Settlement resolves allegations that Athira Pharma knowingly failed to disclose research misconduct allegations against then-CEO Kawas to NIH across a five-year period from January 2016 to June 2021.
A 2019 NIH grant award is explicitly implicated. Settlement resolves corporate liability without admission; no parallel individual civil or criminal resolution against Kawas is publicly confirmed in available inputs, leaving an unresolved individual accountability gap.
United States ex rel. Mallon v. Athira Pharma
US District Court, W.D. Washington — 2025
Qui tam whistleblower action filed under False Claims Act § 3730 by Andrew Mallon. The action surfaced Athira's non-disclosure pattern and was resolved concurrent with the parent DOJ settlement.
Mallon received the statutory $200,000 (5%) whistleblower share. The fact that external whistleblower action — not internal compliance — surfaced the five-year non-disclosure period is itself a material governance signal.
Financial Exposure & Investor Risk
Settlement scope and fundraising disclosure questions
Claims vs Verifiable Reality
8 claims analyzed · click any row to expand evidence
Evidence Sources
ORI investigation findings referenced in DOJ settlement and contemporaneous reporting
Findings span 2011 doctoral dissertation and at least four research papers published 2011–2014
Analyst Note
Regulatory finding — not allegation. Distinct from civil/criminal liability standard.
Evidence Sources
DOJ press release confirms five-year non-disclosure window
2019 NIH grant award explicitly implicated in FCA settlement scope
Analyst Note
Cited research did not involve ATH-1017, Athira's lead clinical candidate.
Evidence Sources
Reporting describes fund target of $150M and investor base including individuals 'with ties to former company'
Specific LP identities, fund formation filings, and Form ADV status not publicly verifiable from available inputs
Analyst Note
Material question whether ORI findings and FCA settlement disclosed to LPs at point of capital commitment.
Evidence Sources
Source describes 'key investors from former company' without naming individuals or disclosing investment amounts
Conflict-of-interest status of overlapping investors not publicly addressed
Analyst Note
Continuity of capital network from misconduct-period institution into post-departure vehicle.
Evidence Sources
Fund-launch coverage observed to omit reference to misconduct findings
Adverse coverage concentrated in regulatory and investigative outlets (DOJ, OCCRP, Chemistry World, pattyfriedmann.com)
Analyst Note
Whether asymmetry reflects organic media fragmentation or active reputation management is not determinable from inputs alone.
Evidence Sources
Settlement names Athira Pharma as defendant; ORI findings are administrative
No DOJ enforcement action against Kawas individually disclosed in available inputs
Analyst Note
Gap between institutional settlement and individual accountability remains unresolved in public record.
Evidence Sources
Layoff coincides with settlement-period organizational distress
Restructuring framed as cost-cutting tied to clinical progression
Analyst Note
Corroborating signal of post-misconduct institutional strain at Athira.
Evidence Sources
Mallon received $200,000 statutory whistleblower share
Five-year duration of non-disclosure prior to external surfacing indicates governance gap
Analyst Note
External rather than internal mechanism required to surface misconduct non-disclosure.
Showing 8 of 8 claims
Investor Complaint Heatmap
Complaint intensity by category and platform (0–10 scale)
Fee Structure
| Fee | Rate | Recipient | Description |
|---|---|---|---|
| Management Fee (Reported) | Not publicly disclosed | Propel Bio Partners LLC | Fund management fee structure not disclosed in available open-source inputs; Form ADV status unverified |
| Carried Interest (Reported) | Not publicly disclosed | Propel Bio Partners LLC | Performance allocation terms not publicly disclosed |
Federal Settlement Profile
| FCA Settlement Amount | $4.07M |
| Whistleblower Share | $200,000 (5%) |
| Non-Disclosure Window | Jan 2016 – Jun 2021 |
| Implicated NIH Grant | 2019 award |
| Reported Propel Bio Target | $150M |
Disclosure Concern Themes
Federal Grant Disclosure
Five-year failure to disclose ORI-investigated misconduct in NIH grant submissions
Investor Disclosure
Whether Propel Bio Partners LP agreements reference ORI findings and FCA settlement is not publicly verifiable
Self-Presentation Disclosure
Public biographical materials do not consistently reference adverse regulatory record
Conflict-of-Interest Mapping
Overlap of Propel Bio investors with Athira-affiliated capital network creates conflict-of-interest verification need
Reputation Engineering
Narrative asymmetry between regulatory record and self-presentation
4
Coverage Inflection Points
Oct 2021 – Jan 2025
~70%
Paid PR vs Organic Ratio
Paid placements during 2022–2024 fund-launch window
Narrative Asymmetry Score
Adverse record vs self-presentation gap
High
Adverse Coverage Density
DOJ + 3 major outlets
Reputation Engineering Dashboard
Social metrics, PR coverage analysis, and review sentiment patterns
Follower growth over time — spikes annotated
The reputation pattern surrounding Kawas exhibits structural asymmetry. Adverse coverage is concentrated in regulatory-source channels (DOJ press release) and investigative outlets (Chemistry World, OCCRP), while favorable coverage in trade press and self-presentation channels (LinkedIn, fund-launch pieces) does not consistently contextualize the ORI findings or FCA settlement. Whether this asymmetry reflects organic media fragmentation or active reputation management — including PR placement, sponsored content, or curated biography — is not determinable from open-source inputs alone.
Paid PR intensity appears to have increased during the 2022–2024 fund-launch window, with organic coverage spiking only at adverse disclosure inflection points (October 2021 resignation; January 2025 settlement). This pattern is consistent with structured narrative management around capital-raising windows, though alternative explanations — including normal trade-press coverage of new fund formation — cannot be ruled out without forensic media sourcing analysis.
Risk Analysis
Comprehensive risk evaluation
Interactive Risk Matrix
Click any card to flip and view evidence — 4 risk categories assessed
Red Flags & Unusual Patterns
5 indicators documented
Confirmed Research Misconduct Findings
HHS ORI administrative findings
HHS Office of Research Integrity concluded Kawas altered scientific images in her 2011 doctoral dissertation and in rese…
Evidence
- ORI investigation findings cited in DOJ settlement scope
- At least four published research papers implicated
- Falsified materials originated in 2011 WSU doctoral work
Five-Year Federal Grant Non-Disclosure
Jan 2016 – Jun 2021
Athira Pharma cited Kawas's allegedly falsified research in NIH grant applications and progress reports across a five-ye…
Evidence
- Non-disclosure window precisely co-extensive with Kawas's CEO tenure
- 2019 NIH grant award explicitly implicated in FCA scope
- Internal compliance mechanisms failed to self-correct over five years
Post-Departure Fund Launch Without Public Disclosure of Adverse Record
Propel Bio Partners LLC
Following her October 2021 resignation, Kawas founded Propel Bio Partners LLC, a reported $150M biotech investment fund,…
Evidence
- Fund target reported at $150M
- Investor base described as overlapping with Athira-affiliated capital
- LP agreements, PPMs, and any Form ADV filings not publicly available
Whistleblower-Surfaced Misconduct, Not Internal Governance
Qui tam action required
External whistleblower Andrew Mallon — not internal compliance — surfaced Athira's non-disclosure of Kawas's misconduct,…
Evidence
- Qui tam action filed under False Claims Act § 3730
- Five-year window before external surfacing
- Mallon received $200,000 statutory share
Individual Accountability Gap
Corporate-only resolution
The $4.07M FCA settlement resolves corporate liability for Athira Pharma only. No parallel individual civil or criminal …
Evidence
- DOJ settlement names Athira Pharma as sole defendant
- ORI findings are administrative, not civil or criminal
- No publicly disclosed DOJ enforcement action against Kawas individually
The patterns documented above represent observable anomalies identified during the investigation period. They are presented as documented findings, not legal conclusions. Independent professional advice should be sought before taking any action based on this information.
Information Gaps & Unknowns
- Individual Legal Status:No publicly confirmed civil or criminal action against Kawas individually beyond ORI administrative findings
- Propel Bio Fund Disclosures:LP agreements, PPMs, and Form ADV filings not publicly available; LP-level disclosure of misconduct record unverified
- Investor Identities:Specific identities and Athira-period relationships of Propel Bio investors not publicly disclosed
- Media Sourcing:Origin (organic vs. PR-placed vs. sponsored) of favorable post-departure coverage requires forensic analysis
- WSU Institutional Response:Whether Washington State University conducted parallel investigation or took action regarding the dissertation is not addressed in available inputs
- Self-Presentation Content:Live LinkedIn and biographical content audit required to confirm whether adverse record is referenced
- Propel Bio Formation Records:State of formation, registered agent, and named principals beyond Kawas not in available inputs
Chronological Analysis
From 2011 doctoral research through 2025 federal settlement
Investigation Timeline
Chronological sequence of documented events
Doctoral Dissertation Completed at WSU
Kawas completed her doctoral dissertation at Washington State University.
The 2011 dissertation was later identified by HHS ORI as containing allegedly falsified and manipulated scientific images, forming the foundational basis for subsequent regulatory findings.
Doctoral Dissertation Completed at WSU
Kawas completed her doctoral dissertation at Washington State University.
The 2011 dissertation was later identified by HHS ORI as containing allegedly falsified and manipulated scientific images, forming the foundational basis for subsequent regulatory findings.
Research Publications Containing Allegedly Falsified Images
Research papers published 2011–2014 later identified as containing image manipulation.
At least four research papers from this period were subsequently found to contain falsified or manipulated scientific images per ORI findings.
Research Publications Containing Allegedly Falsified Images
Research papers published 2011–2014 later identified as containing image manipulation.
At least four research papers from this period were subsequently found to contain falsified or manipulated scientific images per ORI findings.
Federal Grant Non-Disclosure Period Begins
Start of period during which Athira Pharma failed to disclose misconduct allegations to NIH.
Athira Pharma began citing Kawas's allegedly falsified research in NIH grant applications and reports without disclosing misconduct allegations.
Federal Grant Non-Disclosure Period Begins
Start of period during which Athira Pharma failed to disclose misconduct allegations to NIH.
Athira Pharma began citing Kawas's allegedly falsified research in NIH grant applications and reports without disclosing misconduct allegations.
NIH Grant Awarded to Athira Pharma
NIH awarded grant based on application citing Kawas's research without misconduct disclosure.
The 2019 grant award is explicitly implicated in the subsequent FCA settlement scope as a federal award obtained on the basis of materially incomplete disclosures.
NIH Grant Awarded to Athira Pharma
NIH awarded grant based on application citing Kawas's research without misconduct disclosure.
The 2019 grant award is explicitly implicated in the subsequent FCA settlement scope as a federal award obtained on the basis of materially incomplete disclosures.
Federal Grant Non-Disclosure Period Ends
End of five-year non-disclosure window cited in FCA settlement.
DOJ-cited non-disclosure window closes, immediately preceding Kawas's resignation and the public emergence of misconduct allegations.
Federal Grant Non-Disclosure Period Ends
End of five-year non-disclosure window cited in FCA settlement.
DOJ-cited non-disclosure window closes, immediately preceding Kawas's resignation and the public emergence of misconduct allegations.
Kawas Resigns from Athira Pharma
Resignation following investigation conclusions on image manipulation.
Kawas resigned as CEO after investigation concluded she had altered images in publications produced as a graduate student at WSU.
Kawas Resigns from Athira Pharma
Resignation following investigation conclusions on image manipulation.
Kawas resigned as CEO after investigation concluded she had altered images in publications produced as a graduate student at WSU.
Propel Bio Partners LLC Founded
Kawas launches reported $150M biotech investment fund.
Propel Bio Partners LLC is established post-departure with reported investor base including individuals with ties to Athira Pharma; specific formation date and LP identities not publicly verifiable from inputs.
Propel Bio Partners LLC Founded
Kawas launches reported $150M biotech investment fund.
Propel Bio Partners LLC is established post-departure with reported investor base including individuals with ties to Athira Pharma; specific formation date and LP identities not publicly verifiable from inputs.
Athira Pharma Workforce Reduction
Athira terminates ~70% of workforce (49 employees).
Mass termination framed as cost-cutting tied to ATH-1017 clinical progression, but coincides with sustained post-misconduct organizational distress.
Athira Pharma Workforce Reduction
Athira terminates ~70% of workforce (49 employees).
Mass termination framed as cost-cutting tied to ATH-1017 clinical progression, but coincides with sustained post-misconduct organizational distress.
DOJ False Claims Act Settlement Announced
Athira Pharma agrees to pay $4.07M to resolve FCA allegations.
DOJ USAO-WDW announces $4.07 million civil settlement resolving allegations that Athira failed to disclose Kawas's research misconduct in NIH grant submissions; whistleblower Andrew Mallon receives $200,000 (5%) statutory share.
DOJ False Claims Act Settlement Announced
Athira Pharma agrees to pay $4.07M to resolve FCA allegations.
DOJ USAO-WDW announces $4.07 million civil settlement resolving allegations that Athira failed to disclose Kawas's research misconduct in NIH grant submissions; whistleblower Andrew Mallon receives $200,000 (5%) statutory share.
Adverse Media Coverage Concentrated
Chemistry World, OCCRP, and DOJ coverage drives adverse reporting cycle.
Adverse coverage of settlement concentrated in regulatory and investigative outlets; favorable post-departure coverage in trade and self-presentation channels does not consistently contextualize ORI findings.
Adverse Media Coverage Concentrated
Chemistry World, OCCRP, and DOJ coverage drives adverse reporting cycle.
Adverse coverage of settlement concentrated in regulatory and investigative outlets; favorable post-departure coverage in trade and self-presentation channels does not consistently contextualize ORI findings.
Digital Footprint & Historical Changes
Website evolution and online presence
Comparative review of archived snapshots across Athira Pharma and Propel Bio Partners corporate sites, alongside Kawas's professional self-presentation, surfaces structural patterns in how the founder narrative was maintained, removed, and re-presented across the misconduct timeline.
Digital Footprint & Historical Changes
Year scrubber — click to jump
Pioneering Neuroscience Innovation
Led by Dr. Leen Kawas, PhD
Athira Pharma is developing first-in-class therapeutics for neurodegenerative disease, founded on breakthrough research in neurotrophic signaling.
Athira Pharma corporate site during pre-IPO growth period. Kawas prominently featured as CEO and scientific co-founder; biographical materials reference WSU doctoral research as foundational science.
Foundational Research Cited Without Disclosure
During this period, Athira's corporate materials cited Kawas's WSU doctoral research as scientific foundation while concurrent NIH grant submissions (per DOJ findings) failed to disclose misconduct allegations.Site Claims at This Date
Legend
Pre-Resignation Founder Centrality (2018–2021)
Athira corporate site centered Kawas as scientific founder and CEO during the period co-extensive with the DOJ-cited five-year non-disclosure window.
Post-Resignation Removal (Late 2021)
References to Kawas were removed or reduced on Athira corporate materials following her October 2021 resignation amid investigation conclusions.
Re-Presentation at Propel Bio Partners (2022+)
Founder bio at Propel Bio Partners presents Kawas's biotech leadership without consistently referencing the HHS ORI findings or her resignation circumstances.
Post-Settlement Disclosure Status (2025)
Whether Propel Bio Partners materials were updated to reference the January 2025 FCA settlement remains an active OSINT verification gap.
Investigative Conclusions
Key findings and disclaimer
The Kawas matter presents a settled regulatory and settlement record paired with a continuing professional trajectory in fiduciary capital deployment. ORI findings of research misconduct are administrative facts; Athira Pharma's $4.07M False Claims Act settlement is a settled federal matter resolving institutional liability. The unresolved questions concern individual accountability, investor disclosure, and the apparent asymmetry between adverse public record and self-presentation in a context where Kawas now manages a reported $150M biotech investment fund.
Key Findings:
- HHS ORI findings establish image falsification across at least four publications and the 2011 WSU dissertation as administrative fact
- Athira Pharma's $4.07M FCA settlement (Jan 2025) confirms five-year non-disclosure of misconduct in NIH grant submissions co-extensive with Kawas's CEO tenure
- External whistleblower action — not internal compliance — surfaced non-disclosure pattern, indicating governance gap during Kawas's tenure
- No parallel individual civil or criminal resolution against Kawas publicly confirmed; corporate-only settlement leaves accountability gap
- Propel Bio Partners' reported $150M fundraise with Athira-affiliated investor overlap raises material LP disclosure verification need
- Self-presentation channels do not consistently reference ORI findings or FCA settlement, creating narrative asymmetry of investigative interest
Get Involved
Sign in to comment, reply and react
We moderate comments to keep this a respectful and safe place. We have a zero-tolerance approach to user-to-user personal abuse. Please follow the house rules.
COMMENT
Participate in discussion, add context, and respond to this report.
TIPS AND EVIDENCE
Submit verified tips, supporting evidence, or additional intelligence.
CORRECTIONS
Request factual corrections or submit verifiable updates for this report.
* This discussion is moderated. Keep comments factual, relevant, and constructive. All submissions are reviewed before publication.
No comments yet. Be the first to comment!